JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

Search

Relay Therapeutics Inc

Fermé

SecteurSoins de santé

6.86 -1.01

Résumé

Variation du prix de l'action

24h

Actuel

Min

6.74

Max

7.03

Chiffres clés

By Trading Economics

Revenu

6.7M

-70M

Ventes

-7M

677K

Marge bénéficiaire

-10,395.126

Employés

197

EBITDA

8M

-77M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+97.55% upside

Dividendes

By Dow Jones

Prochains Résultats

6 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

647M

1.3B

Ouverture précédente

7.87

Clôture précédente

6.86

Sentiment de l'Actualité

By Acuity

50%

50%

156 / 373 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Relay Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 nov. 2025, 21:44 UTC

Résultats

Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs

3 nov. 2025, 23:44 UTC

Market Talk

Nikkei May Rise on Weaker Yen, Hopes for Govt Econ Steps -- Market Talk

3 nov. 2025, 23:34 UTC

Market Talk

Gold Edges Lower Amid Lingering Worry Over China's Ending of Tax Incentive -- Market Talk

3 nov. 2025, 23:28 UTC

Résultats

Palantir Revenue Hits Another Record as Defense Work Booms -- 2nd Update

3 nov. 2025, 23:24 UTC

Résultats

Correct: Grab Holdings Sees FY2025 Adj Ebitda $490M-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3 nov. 2025, 23:14 UTC

Market Talk
Acquisitions, Fusions, Rachats

Global Equities Roundup: Market Talk

3 nov. 2025, 23:14 UTC

Market Talk
Acquisitions, Fusions, Rachats

Deterra's Next CEO Might Bring New Approach to Deals -- Market Talk

3 nov. 2025, 23:12 UTC

Résultats

Grab Holdings Sees FY2025 Adj Ebitda $490-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3 nov. 2025, 23:09 UTC

Résultats

Grab Holdings 3Q 2Q Adj EBITDA $136.0M Vs. $90.0M>GRAB

3 nov. 2025, 23:09 UTC

Résultats

Grab Holdings 3Q Net $17.0M Vs. Net $15.0M >GRAB

3 nov. 2025, 23:09 UTC

Résultats

Grab Holdings 3Q Rev $873.0M Vs. $716.0M >GRAB

3 nov. 2025, 23:06 UTC

Market Talk
Résultats

Palantir Execs Forecast Future of U.S. Workers In AI World -- Market Talk

3 nov. 2025, 22:36 UTC

Market Talk
Résultats

Palantir's U.S. Commercial Business Booms as It Expands AI -- Market Talk

3 nov. 2025, 22:31 UTC

Résultats

Franco-Nevada 3Q EPS $1.49 >FNV

3 nov. 2025, 22:31 UTC

Résultats

Franco-Nevada 3Q Rev $487.7M >FNV

3 nov. 2025, 22:24 UTC

Market Talk

Xero Bulls Expect Improving U.S. Momentum in 1H -- Market Talk

3 nov. 2025, 22:19 UTC

Acquisitions, Fusions, Rachats

Starbucks Agrees to Sell Stake in China Business -- WSJ

3 nov. 2025, 21:59 UTC

Market Talk

RBA Set To Keep Rates On Hold; Remain Data Dependent -- Market Talk

3 nov. 2025, 21:54 UTC

Market Talk
Résultats

Westpac's Tech Challenge Keeps Jefferies Cautious -- Market Talk

3 nov. 2025, 21:54 UTC

Market Talk
Résultats

Global Equities Roundup: Market Talk

3 nov. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 nov. 2025, 21:49 UTC

Résultats

Palantir Revenue Hits Another Record as Defense Work Booms -- Update

3 nov. 2025, 21:40 UTC

Résultats

Barry Diller's IAC Inks AI Deal With Microsoft. That Isn't Why the Stock Is Sliding. -- Barrons.com

3 nov. 2025, 21:31 UTC

Market Talk

Mexican Manufacturing Indexes Pick Up in October -- Market Talk

3 nov. 2025, 21:19 UTC

Résultats

Palantir Revenue Hits Another Record as Defense Work Booms -- WSJ

3 nov. 2025, 21:11 UTC

Acquisitions, Fusions, Rachats

Pfizer Reports Earnings Tuesday. Management Has Big Questions to Answer. -- Barrons.com

3 nov. 2025, 21:11 UTC

Résultats

Diamondback Energy: Increasing Full Yr Oil Production Guidance to 495-498 MBO/d and Increasing Annual BOE Guidance to 910-920 MBOE/d >FANG

3 nov. 2025, 21:07 UTC

Résultats

Palantir Technologies: Raising 2025 U.S. Comml Rev Guidance to in Excess of $1.433B, Representing a Growth Rate of at Least 104% >PLTR

3 nov. 2025, 21:05 UTC

Résultats

Vertex Pharmaceutic Sees 2025 Rev $11.9B-$12B >VRTX

3 nov. 2025, 21:05 UTC

Résultats

Palantir Technologies 3Q Net $475.6M >PLTR

Comparaison

Variation de prix

Relay Therapeutics Inc prévision

Objectif de Prix

By TipRanks

97.55% hausse

Prévisions sur 12 Mois

Moyen 13.71 USD  97.55%

Haut 19 USD

Bas 4 USD

Basé sur 9 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

9 ratings

7

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

2.88 / 3.285Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

No Evidence

Sentiment

By Acuity

156 / 373Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Moyen

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat